VANCOUVER, BC and TOKYO, March 3, 2026 /PRNewswire/ – The International Society for Cell & Gene Therapy (ISCT), the translation-focused global community of cell and gene therapy experts and the Japanese Society for Regenerative Medicine (JSRM), advancing iPSC-based therapies, jointly announce a 5-year strategic partnership to advance iPSC-based therapies globally.

The ISCT–JSRM Joint Strategic Collaboration on Clinical iPSCs represents a landmark in the history of international regenerative medicine collaboration. Building on the International Society for Cell & Gene Therapy’s (ISCT) three-decade legacy of translating cell and gene therapy research into safe, effective, and accessible therapies worldwide, and the Japanese Society for Regenerative Medicine’s (JSRM) pioneering role in translational research, including the world’s first clinical application of iPSC-derived cells, the mission of this collaboration is to advance developments towards a global infrastructure that enables access to safe and effective iPSC-based therapies.

“There are big challenges ahead. By leveraging the networks and expertise of both ISCT and JSRM, however, we will create a meaningful global collaboration that will set a standard of knowledge, of approach, and of integration,” said Masayo Takahashi, MD, PhD, JSRM Chair for the ISCT-JSRM Joint Collaboration. “Working together, we will accelerate harmonization across key sectors in regulation, medicine, and industry, so that patients not only in Japan, but across the globe, can benefit.”

“This is a formative time for iPSCs. The first rigorous clinical trials are beginning to be reported, particularly in Japan. Regulatory structures have been framed but need to be harmonized internationally. Automated platforms for high quality manufacturing for single individuals and large populations are coming online. Our ISCT-JSRM Collaboration is an essential forum for clinicians, scientists, industry, regulators, patients, and payors to share new data and distill opportunities into targeted, safe, effective, and accessible therapies.” said George Muschler, MD, ISCT Chair for the ISCT-JSRM Joint Collaboration.

The ISCT–JSRM Joint Collaboration is a continuous, outcomes-focused initiative that will identify emerging bottlenecks, develop and implement solutions, and deliver measurable progress year after year for the sector. By convening expertise from across the globe, this collaboration will construct an infrastructure that fully realizes the social and economic value of clinical iPSCs.

A Strategic Five-Year Vision

Beginning in 2026 at the 25th JSRM Annual Meeting in Kobe, the birthplace of human iPSC transplantation, the Joint Collaboration will host annual events to share insights into key challenges being addressed and provide updates on the Collaboration’s activities. These events will alternate annually between JSRM and ISCT annual meetings.

“Alongside ISCT, we see the pathway ahead to fulfilling the promise of iPSCs at a global scale. We are excited to work together on these key events, so that we can both bring our work to the global table, and also learn from others in the CGT space, especially those clinical and regulatory developments that will further shape our success,” said Kohji Nishida, MD, PhD, President of JSRM.

The ISCT-JSRM Collaboration will prioritize and advance developments in the following areas:

Advance clinical translation through shared expertise in trial design, patient recruitment, real-world data integration, and multinational trial networks.
Drive technological innovation by setting global safety characterization standards, integrating AI and automation, and enabling scalable, cost-effective manufacturing.
Enable regulatory innovation that reduces approval timelines for iPSC-products without increasing risks for patients.
Harmonize regulations across jurisdictions to accelerate approval pathways, reduce operational costs, and ensure consistent GMP standards.
Educate and train across sectors — building capacity from laboratory research to commercial manufacturing, policy, and patient advocacy.
Promote commercial realization through sustainable reimbursement models and early engagement between developers and payors.
Strengthen medical affairs to connect clinical evidence with regulators and policymakers

“iPSCs provide a unique opportunity for the CGT field as research begins to mature into therapies. There is no stronger foundation here than a proven clinical application, and JSRM has been a driving force in building that foundation,” said Miguel Forte, MD, PhD, President of ISCT. “Together with our partners at JSRM, ISCT will leverage its global network to drive advancement from foundation to ecosystem, from region to globe. Success here will blaze a trail for other CGT platforms that are advancing at an accelerating pace.”

ISCT and JSRM acknowledge the leadership and dedication of the Joint Collaboration’s Organizing Committee, comprised of leaders from both organizations, in advancing this landmark international initiative.

About the International Society for Cell & Gene Therapy

Established in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective treatments to improve lives worldwide.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses critical areas of translation: Academia, Regulatory, Commercialization, and Clinical. Through solid relationships with global regulatory agencies, academic institutions, industry partners, and clinical leaders, ISCT drives the advancement of research to standard of care.

Comprising over 4,500 cell and gene therapy experts across five geographic regions and with representation from over 60 countries, ISCT members are a global community of peers, thought leaders, and organizations invested in cell and gene therapy translation. For more information about the society, key initiatives, and upcoming meetings, please visit https://isctglobal.org.

About the Japanese Society for Regenerative Medicine

JSRM is the largest academic society in regenerative medicine globally, with over 6,000 members spanning diverse fields, including basic and clinical sciences, tissue engineering, bioethics, regulatory science, and health policy. JSRM serves as a multidisciplinary platform for researchers, clinicians, industry leaders, and policymakers to collaborate on regenerative medicine development and implementation. The society actively engages in policy advocacy, develops industry standards, and hosts international academic conferences to drive scientific and regulatory advancements in regenerative medicine.

For more information about JSRM, please visit https://en.jsrm.jp/

View original content to download multimedia:https://www.prnewswire.com/news-releases/isctjsrm-5-year-joint-strategic-collaboration-on-clinical-ipscs-launches-inaugural-joint-collaboration-in-kobe-japan—march-21-2026-302702761.html